Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumococcal vaccine GSK2189241A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Formulation 1 | EXPERIMENTAL | - |
| Formulation 2 | EXPERIMENTAL | - |
| Formulation 3 | EXPERIMENTAL | - |
| Formulation 4 | EXPERIMENTAL | - |
| Formulation 5 | EXPERIMENTAL | - |
| Formulation 6 | EXPERIMENTAL | - |
| 23 valent pneumococcal vaccine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Pneumococcal vaccine GSK2189241A | BIOLOGICAL | Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. |
| Pneumo 23™ | BIOLOGICAL | One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2. |
Inclusion Criteria: * Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study. * Male or female subjects between, and including, 65 and 85 years old at the time of the first vaccination, in relatively stable health. * Written informed...
Pneumococcal vaccine GSK2189241A is an investigational vaccine developed by GSK plc for infections caused by streptococcal bacteria, specifically pneumococcal disease. It is a Phase 1 candidate and has not been approved for use. It was studied in a single completed clinical trial in elderly healthy volunteers.
Pneumococcal vaccine GSK2189241A is being developed for the prevention of streptococcal infections, the bacterial infections that include pneumococcal disease. Its only recorded clinical study enrolled healthy volunteers aged 65 years and older, so the investigated use is prevention in an elderly population.
Pneumococcal vaccine GSK2189241A is developed by GSK plc, which trades under the ticker GSK. The vaccine candidate is part of the company's infectious disease pipeline and is identified by the internal code GSK2189241A.
Pneumococcal vaccine GSK2189241A is in Phase 1 clinical development. It is an investigational vaccine and is not approved for any indication. One Phase 1 trial has been completed, and no trials are currently listed as active.
Pneumococcal vaccine GSK2189241A has been studied in one completed Phase 1 trial, NCT00756067, titled Evaluation of Pneumococcal Vaccine Formulations in Elderly. The trial enrolled 168 healthy volunteers aged 65 years and older in Sweden and used a randomized, double-blind, active-controlled design.